Initial experience with XXXX in 2nd-, 3rd- and 4th-line therapy for metastatic @entity1358 : good clinical response.

@entity1 @entity13850 @entity55 @entity5 @entity1353 @entity1358
PURPOSE: To report our experience with @entity13850 in 2nd-, 3rd- and 4th-line therapy for @entity1 with @entity1358 ( @entity1358 ). @entity1 AND METHODS: In our prospectively maintained @entity5 registry, we identified 6 @entity1358 @entity1 with @entity13850 in >1st-line systemic therapy. @entity1 were followed by weekly clinical and laboratory examination during admission of @entity13850 . Re-staging with chest CT and abdominal MRI was performed every 3 months. RESULTS: We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, @entity55 was observed in 4 of 6 @entity1 . Drug-related @entity55 led to severe @entity1353 , with the result that treatment with @entity13850 had to be interrupted for a short period of time in 2 @entity1 and discontinued in 1 @entity1 . CONCLUSIONS: @entity13850 proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of @entity55 must not be underestimated.
